Navigation Links
Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma

NEW YORK, March 24, 2017 /PRNewswire/ --

On Thursday, March 23, 2017, the NASDAQ Composite ended the trading session at 5,817.69, down 0.07%; the Dow Jones Industrial Average edged 0.02% lower, to finish at 20,656.58; and the S&P 500 closed at 2,345.96, marginally dropping 0.11%. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. This Friday, has initiated reports coverage on the following Biotechnology equities: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Sage Therapeutics Inc. (NASDAQ: SAGE), Benitec Biopharma Ltd (NASDAQ: BNTC), and OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI). Learn more about these stocks by downloading their free research reports in PDF format at:

BioDelivery Sciences  

On Thursday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended the session 0.26% lower at $1.92 with a total volume of 344,458 shares traded. BioDelivery Sciences International's shares have advanced 1.32% in the past three months. The stock is trading 1.10% below its 50-day moving average and 12.90% below its 200-day moving average. Moreover, shares of the Company, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have a Relative Strength Index (RSI) of 47.27. Sign up and read the free research report on BDSI at:

Sage Therapeutics  

On Thursday, shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. recorded a trading volume of 374,883 shares. The stock ended the day 1.35% lower at $65.09. Sage Therapeutics' stock has gained 5.10% in the last one month and 36.97% in the previous three months. Furthermore, the stock has rallied 123.68% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 11.82% and 40.22%, respectively. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 52.04. The complimentary research report on SAGE can be downloaded at:

Benitec Biopharma  

North Sydney, Australia headquartered Benitec Biopharma Ltd's stock finished Thursday's session 0.43% lower at $2.27 with a total volume of 27,331 shares traded. Over the last three months and the previous one year, Benitec Biopharma's shares have surged 59.42% and 29.72%, respectively. The Company's shares are trading above its 200-day moving average by 29.63%. Shares of Benitec Biopharma, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia, the UK, and the US, have an RSI of 45.10. Register for free on and access the latest report on BNTC at:

OncoGenex Pharma  

Bothell, Washington headquartered OncoGenex Pharmaceuticals Inc.'s stock edged 0.23% lower, to close the day at $0.48. The stock recorded a trading volume of 80,068 shares. OncoGenex Pharma's shares have advanced 4.54% in the last three months. The Company's shares are trading 14.00% and 22.56% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops and commercializes therapies that address treatment resistance in cancer patients, have an RSI of 35.44. Get free access to your research report on OGXI at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
2. Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care
3. Three Day Biotechnology for the Non-Biotechnologist Course (London, United Kingdom - September 27-28-29, 2017) - Research and Markets
4. Festo Introduces at Interphex a New Family of Sanitary/Automated Ball, Angle Seat, and Pinch Valves for the Pharma and Biotech Industries
5. The Next Big Biotech Breakthrough Could Just be on the Horizon
6. Lifecycle Biotechnology Today Announced the Hiring of Aaron Benz as Business Development Manager for their Chemical and Reagent Brand, Chata Biosystems
7. Global Licensing Partnering Report: Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016 - Research and Markets
8. Biotech Sector Influencing Growth in the Pharmaceutical Consulting Services
9. Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima
10. Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma
11. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
Post Your Comments:
(Date:12/5/2018)... ... December 05, 2018 , ... Leading authority on how to bridge the ... his “The Referral Playbook: How to Increase Sales with Proven Networking Strategies.” ... go to the Alzheimer’s Foundation of America (AFA). , Itzkowich is hosting “The ...
(Date:12/5/2018)... CHARLOTTESVILLE, Va. and LONDON (PRWEB) , ... ... ... Atlantic Research Group (ARG), an established North American full-service contract research organization ... CRO. Effective immediately, the transaction significantly strengthens ARG’s reach and experience in ...
(Date:11/27/2018)... , ... November 27, 2018 , ... New patients in ... Dr. Dan Myers’ practice for treatment, with or without a referral. Dr. Myers has ... tools, including porcelain veneers, dental implants, bridges and custom crowns. , As a ...
(Date:11/20/2018)... ... 19, 2018 , ... Patients with missing teeth in Sandy Springs, GA, Alpharetta, ... Dan Myers at THE DENTIST Centers without a referral. Dr. Myers is a skilled ... 20 years. He now offers skilled dental care in two practice locations THE DENTIST ...
Breaking Biology Technology:
(Date:12/5/2018)... YORK (PRWEB) , ... December 03, 2018 , ... ... Cartessa Aesthetics , an emerging leader in the distribution and marketing of ... experienced rapid growth, projecting $20MM in sales for 2018. Cartessa’s success can ...
(Date:12/5/2018)... (PRWEB) , ... December 04, 2018 , ... ... has announced the much-anticipated launch of their 100-liter (26 gallon) SAFEthread Drum. ... Drum in 2017, which brought a much-needed modern redesign to the plastic ...
(Date:11/29/2018)... ... November 29, 2018 , ... ACEA Biosciences , now ... Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a ... and technologies for the consistent, scalable and low-cost production of high-quality living therapeutic ...
Breaking Biology News(10 mins):